 |
|
New authority codes - PBS website - below is a list of some of the most commonly prescribed authority scripts but there are 17 pages of other new codes on the PBS site - please let us know if you wish to add any other drugs to the table below. [Search]
| ACAMPROSATE CALCIUM | Campral | For use within a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence. Note: No applications for increased maximum quantities and/or repeats will be authorised. |
|
| ALENDRONATE SODIUM | Alendro Fosamax |
Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less. The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated. Note: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate. |
|
| Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. |
|||
| ALENDRONATE SODIUM with COLECALCIFEROL | Fosamax Plus | Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less. The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated. Note: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate. |
|
| Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. |
|||
| AMISULPRIDE | Solian | Schizophrenia | |
| ARIPIPRAZOLE | Abilify | Schizophrenia. | |
| BISOPROLOL FUMARATE | Bicor | Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated. | |
| CARVEDILOL | Dilatrend Carvedilol GenRx Kredex |
Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated; | |
| Patients receiving this drug as a pharmaceutical benefit prior to 1 August 2002. | |||
| CLOPIDOGREL HYDROGEN SULFATE | Iscover Plavix |
Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin; | |
| Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding; Note: Not for prophylaxis of DVT or peripheral arterial disease. |
|||
| Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs; Note: Not for prophylaxis of DVT or peripheral arterial disease. |
|||
| Prevention of recurrence of myocardial infarction or unstable angina in patients with a history of symptomatic cardiac ischaemic events while on therapy with low-dose aspirin; Note: Not for prophylaxis of DVT or peripheral arterial disease. |
|||
| Prevention of recurrence of myocardial infarction or unstable angina in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding; Note: Not for prophylaxis of DVT or peripheral arterial disease. |
|||
| Prevention of recurrence of myocardial infarction or unstable angina in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs. Note: Not for prophylaxis of DVT or peripheral arterial disease. |
|||
| DESMOPRESSIN ACETATE | Minirin | Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm; Note: Not to be used in preference to enuresis alarms. |
|
| Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated. Note: Not to be used in preference to enuresis alarms. |
|||
| Cranial diabetes insipidus | |||
| EZETIMIBE | Ezetrol | Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) is unsuitable because the patient developed a clinically important product-related adverse event during treatment with a statin, and required discontinuation of all statin treatment. A clinically important product-related adverse event is defined as follows: (i) Severe myalgia (muscle symptoms without CK elevation) which is proven to be temporally associated with statin treatment; or (ii) Myositis (clinically important CK elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin. |
|
| coronary heart disease Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have: |
|||
| diabetes mellitus Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have diabetes mellitus |
|||
| peripheral vascular disease Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have peripheral vascular disease |
|||
| heterozygous familial hypercholesterolaemia; Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have heterozygous familial hypercholesterolaemia |
|||
| symptomatic cerebrovascular disease Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have symptomatic cerebrovascular disease |
|||
| EZETIMIBE | Ezetrol | 2650 2651 2652 2653 |
Inadequate control with a statin is defined as follows: (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated. |
| EZETIMIBE with SIMVASTATIN | Vytorin | coronary heart disease Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have coronary heart disease |
|
| diabetes mellitus Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have diabetes mellitus |
|||
| peripheral vascular disease Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have peripheral vascular disease |
|||
| heterozygous familial hypercholesterolaemia Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have heterozygous familial hypercholesterolaemia |
|||
| cerebrovascular disease which has become symptomatic Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have cerebrovascular disease which has become symptomatic |
|||
| EZETIMIBE with SIMVASTATIN | Vytorin | 2655 2656 2657 2658 |
Inadequate control with a statin is defined as follows: (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated. |
| EZETIMIBE with SIMVASTATIN | Vytorin | homozygous familial hypercholesterolaemia Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs). |
|
| GABAPENTIN page 7 and page 8 |
Gabapentin Gantin Neurontin Nupentin Gabahexal Pendine |
Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs | |
| LAMOTRIGINE page 9; page 10 and page 11 |
Lamictal Lamogine Lamitrin Elmendos Lamidus Lamotrigine Lamotrigine-DP Seaze |
Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs | |
| LEVODOPA with CARBIDOPA page 11 and page 12 |
Sinemet CR | Parkinson's disease where fluctuations in motor function are not adequately controlled by frequent dosing with conventional formulations of levodopa with decarboxylase inhibitor. [See other codes & combinations of this drug page 11 & page 12 PBS codes list] |
|
| LEVODOPA with CARBIDOPA and ENTACAPONE page 11 and page 12 |
Stalevo | Parkinson's disease in patients being treated with levodopa—decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect; | |
| Parkinson's disease in patients stabilised on concomitant treatment with levodopa—decarboxylase inhibitor combinations and entacapone | |||
| METOPROLOL SUCCINATE | Toprol-XL | Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated. | |
| MONTELUKAST SODIUM | Singulair | children aged 2 to 5 years First-line preventer medication, as the single preventer agent for children aged 2 to 5 years with frequent intermittent or mild persistent asthma, as an alternative to sodium cromoglycate or nedocromil sodium. |
|
| children aged 6 to 14 years First-line preventer medication, as the single preventer agent for children aged 6 to 14 years with frequent intermittent or mild persistent asthma, as an alternative to sodium cromoglycate or nedocromil sodium. |
|||
| OLANZAPINE | Zyprexa Zyprexa Zydis |
Schizophrenia | |
| Maintenance treatment of bipolar I disorder | |||
| PIOGLITAZONE HYDROCHLORIDE | Actos |
Dual oral combination therapy with metformin or a sulfonylurea Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated.
Note:
Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:
(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or |
PIOGLITAZONE HYDROCHLORIDE | Actos |
Combination therapy with insulin Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with insulin and oral anti-diabetic agents, or insulin alone where metformin is contraindicated.
The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated.
Note:
Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:
(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or |
| QUETIAPINE FUMARATE | Seroquel | Schizophrenia. | |
| RALOXIFENE HYDROCHLORIDE | Evista |
Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Note: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate. |
|
| RISEDRONATE SODIUM | Actonel | Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Note: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate. |
|
| Symptomatic Paget's disease of bone | |||
| RISPERIDONE page 14 and page 15 |
Risperdal Quicklet |
dementia Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful. Caution: In placebo controlled trials in elderly patients with dementia there was a significantly higher incidence of cerebrovascular adverse events, such as stroke (including fatalities) and transient ischaemic attacks, in patients treated with risperidone compared with patients treated with placebo. |
|
| bipolar I Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder. |
|||
| Schizophrenia | |||
| autism- paed. behaviour disturbances, severe; Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a child or adolescent aged less than 18 years with autism. Behaviour disturbances are defined as severe aggression and injuries to self or others whesevere behavioural disturbances in a child or adolescent aged less than 18 years with autismre non-pharmacological methods alone have been unsuccessful.. The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders. |
|||
| ROSIGLITAZONE MALEATE page 15 and page 16 |
Avandia Avandamet |
Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with metformin and where a sulfonylurea is contraindicated or not tolerated. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated. Note: Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances: (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or (b) red cell transfusion within the previous 3 months. A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records. |
|
| ROSIGLITAZONE MALEATE page 15 and page 16 |
Avandia Avandamet |
Type 2 diabetes, in combination with a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with maximally tolerated doses of metformin and a sulfonylurea. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated. Note: Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances: (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or (b) red cell transfusion within the previous 3 months. A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records. |
|
| ROSIGLITAZONE MALEATE page 15 and page 16 |
Avandia |
Dual oral combination therapy with metformin or a sulfonylurea Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated. Note: Rosiglitazone maleate is not PBS-subsidised as monotherapy.
Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:
(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or |
|
| ROSIGLITAZONE MALEATE page 15 and page 16 |
Avandia |
Combination therapy with insulin Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with insulin and oral anti-diabetic agents, or insulin alone where metformin is contraindicated. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated. Note: Rosiglitazone maleate is not PBS-subsidised as monotherapy.
Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:
(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or |
|
| ROSIGLITAZONE MALEATE page 15 and page 16 |
Avandia |
Triple oral combination therapy with metformin and a sulfonylurea Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with maximally tolerated doses of metformin and a sulfonylurea. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated. Note: Rosiglitazone maleate is not PBS-subsidised as monotherapy.
Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:
(a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or |
|
| STRONTIUM RANELATE | Protos |
Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Note: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate. |
|
| SUMATRIPTAN | Imigran Nasal spray |
Migraine attacks in patients receiving, or who have failed a reasonable trial of, prophylactic medication and where attacks in the past have usually failed to respond to oral therapy with ergotamine and other appropriate agents, or in whom these agents are contraindicated.
Note: |
|
| SUMATRIPTAN SUCCINATE | Imigran FDT Imigran Sumatab Suvalan |
Migraine attacks in patients receiving, or who have failed a reasonable trial of, prophylactic medication and where attacks in the past have usually failed to respond to oral therapy with ergotamine and other appropriate agents, or in whom these agents are contraindicated. Note: No applications for increased maximum quantities and/or repeats will be authorised. |
|
| TICLOPIDINE HYDROCHLORIDE | Ticlopidine Hexal Ticlid Tilodene |
Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin; | |
| Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding; | |||
| Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs; | |||
| Patients established on this drug as a pharmaceutical benefit prior to 1 November 1999. | |||
| VIGABATRIN | Sabril | Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs. | |
| ZIPRASIDONE HYDROCHLORIDE | Zeldox | Schizophrenia | |
